Announcement of the Conflict and Coordination of China's Drug Patent Compulsory Licensing System under the Health Crisis

Yunan YangAdvances 2022 · DOI · OpenAlex

Abstract Public health is currently a significant issue in growing China and even on a worldwide scale. SARS, H1N1, H7N9 avian influenza, and the recent outbreak of coronary pneumonia are just a few of the significant health and safety disasters that have significantly jeopardized public health in our nation in the first two decades of the twenty-first century. One of the most challenging concerns affecting Chinese people's ability to support themselves has been the public health problem. This paper examines the current state of the difficulties in implementing the compulsory licensing system for pharmaceuticals in China, compares the provisions and implementation of the system in developed and developing nations, such as India and Brazil, and reviews pertinent literature to highlight the deficiencies of the compulsory licensing system for pharmaceuticals in China and offer suggestions for improvement.

Introduction: The Public Health Imperative

In the first two decades of the 21st century, China has faced a series of significant health and safety disasters, ranging from SARS and H1N1 to the global COVID-19 pandemic. These crises have underscored a fundamental tension in modern governance: the conflict between protecting intellectual property (IP) to incentivize innovation and ensuring the public's right to affordable, life-saving medicine. While pharmaceutical patents are essential for recouping research and development costs, they often result in high drug prices that place essential treatments out of reach for the general population. In China, where medical costs reached approximately 3.5 trillion RMB as early as 2014, this "patent vs. patients" dilemma has become a critical barrier to sustainable public health.

Compulsory licensing is a legal mechanism recognized internationally under the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement, specifically Article 31. It allows a government to authorize the production of a patented product by a third party without the patent holder's consent, typically in exchange for a royalty fee. This system is designed as a safety valve for public health emergencies, ensuring that monopolies do not prevent the distribution of essential vaccines or drugs.

However, in China, this system remains entirely "dormant." Despite having the necessary provisions within its Patent Law, the Chinese government has never triggered a compulsory license. This paper investigates the systemic barriers that have kept this legal tool in a state of theoretical existence rather than practical application.

Comparative Analysis: Global Implementations

The implementation of compulsory licensing varies significantly between developed and developing nations:

  • Developing Nations (India, Brazil, Thailand): These countries have frequently utilized compulsory licensing to address urgent health crises, such as HIV/AIDS and cancer. By prioritizing the "right to life and health," they have successfully lowered the cost of essential medicines through generic production.
  • Developed Nations (USA, Germany): In wealthier nations, compulsory licensing is more often employed as a remedy for antitrust violations or to ensure competition, rather than as a primary tool for public health access. For example, the German Patent Law of 1877 established early precedents for balancing inventor rights with public interest.

Identifying Systemic Barriers in China

The research identifies several key reasons why China's system has failed to activate:

1. The Generic Drug Approval Bottleneck

A major hurdle is the disconnect between patent law and drug administration. China’s rigorous generic drug approval process currently requires manufacturers to complete three clinical trials. This process is so lengthy that even if a compulsory license were granted during a crisis, the resulting generic drugs might not reach the market until the emergency has passed.

2. Lack of Actionable Legislation

While the Patent Law provides the broad authority for compulsory licensing, the Drug Administration Law lacks the specific, granular rules required to manage the process. Without a clear "trigger" list defining which diseases or emergencies qualify, administrative bodies are hesitant to act.

3. The Innovation Loop Conflict

There is a persistent fear that aggressive use of compulsory licensing will stifle domestic innovation. Patents create a positive feedback loop for pharmaceutical companies; without the ability to recoup costs, future R&D may stall. The author argues that the current high-cost model is unsustainable if it jeopardizes the public's fundamental rights.

Strategic Recommendations for Reform

To move the system from theory to implementation, the paper proposes several strategic shifts:

  • Classification and Trigger Systems: The government should establish a clear classification system for compulsory licensing based on levels of urgency and specific public interest needs (e.g., distinguishing between acute pandemics and chronic diseases like heart disease).
  • Legislative Integration: The Drug Administration Law must be amended to include actionable rules for managing licenses, including a "fast-track" approval process for generics produced under these specific conditions.
  • Administrative Oversight and Tracking: To prevent market abuse and ensure safety, drugs produced under compulsory licenses should be labeled with unique barcodes. This facilitates tracking and ensures these medicines are used strictly for the intended public health purpose.
  • Balanced Royalties: The system must ensure that patent holders receive fair royalties. This maintains a level of incentive for innovation while prioritizing the immediate health needs of the citizenry.

Conclusion

China's compulsory licensing system for pharmaceuticals is currently a "paper tiger"—legally present but practically absent. As the nation continues to navigate an aging population and potential future health crises, revitalizing this system is essential. By harmonizing patent protections with the fundamental right to health through legislative reform and administrative clarity, China can create a more resilient and equitable public health infrastructure.

Summary updated

Abstract

Public health is currently a significant issue in growing China and even on a worldwide scale.SARS, H1N1, H7N9 avian influenza, and the recent outbreak of coronary pneumonia are just a few of the significant health and safety disasters that have significantly jeopardized public health in our nation in the first two decades of the twenty-first century.One of the most challenging concerns affecting Chinese people's ability to support themselves has been the public health problem.This paper examines the current state of the difficulties in implementing the compulsory licensing system for pharmaceuticals in China, compares the provisions and implementation of the system in developed and developing nations, such as India and Brazil, and reviews pertinent literature to highlight the deficiencies of the compulsory licensing system for pharmaceuticals in China and offer suggestions for improvement.
BibTeX
@inproceedings{yang2022announcement,
  author = {Yunan Yang},
  title = {{Announcement of the Conflict and Coordination of China's Drug Patent Compulsory Licensing System under the Health Crisis}},
  booktitle = {Advances},
  year = {2022},
  doi = {10.2991/978-2-494069-89-3\_120},
}
Figure